KIFC1 and cancer: Although the reasons for the limited specificity of these compounds is not fully understood, it seems likely to be a pharmacological issue of these first-generation inhibitors, rather than a biological problem of targeting KIFC1, as several studies have demonstrated a cancer-specific requirement for KIFC1 when using siRNA mediated KIFC1 knockdown [12,25,53].